Effectiveness and safety of endoscopic ultrasound-guided radiofrequency ablation for pancreatic metastases of renal cell carcinoma.

Abstract

Background and study aims

Pancreatic metastases from renal cell carcinoma (RCC) are usually managed surgically but with significant morbidity. As an alternative, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has shown promising results in treatment of pancreatic neuroendocrine tumors. The aim of our study was to assess technical success, effectiveness, and safety of EUS-RFA in patients with pancreatic metastases of RCC.

Patients and methods

This retrospective, observational study included consecutive patients referred for EUS-RFA of pancreatic RCC metastases. EUS-RFA was performed through 18G or 19G dedicated RFA needles. Effectiveness of EUS-RFA treatment was defined by necrosis with no contrast enhancement or lesion disappearance, determined by contrast-enhanced computed tomography (CT) scan, at 2 to 5 months post procedure, 1 year, and at the end of follow-up. Safety was assessed per and post procedure.

Results

Between January 2015 and January 2021, eight patients with 11 lesions were treated and median time from RCC diagnosis to pancreatic metastases RFA was 8.5 years (1–15). Mean lesion size was 13.9 mm (± 3.9). Technical success assessed by immediate post procedure contrast-enhanced CT or Doppler was 100%. At the first CT scan follow-up, complete response was 45.4% and partial response was 27.3%. At 1 year, complete response was 45.4% and partial response was 27.3%. Three patients had multiple EUS-RFAs. Adverse events occurred in 3 patients (mild acute pancreatitis, abdominal pain, and pancreatic fistula with retro-gastric pseudocyst).

Conclusions

Our study demonstrated the feasibility and safety of EUS-RFA for patients with pancreatic metastases of RCC.

Keywords

Endoscopic ultrasonography - Pancreas - Intervention EUS

Publikationsverlauf

Eingereicht: 11. September 2024

Angenommen nach Revision: 25. Januar 2025

Accepted Manuscript online:
25. März 2025

Artikel online veröffentlicht:
12. Mai 2025

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30
• 2 Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J 2010; 7: 1-9
• 3 Ballarin R. Pancreatic metastases from renal cell carcinoma: The state of the art. World J Gastroenterol 2011; 17: 4747
• 4 Hirashita T, Iwashita Y, Endo Y. et al. How should we treat pancreatic metastases from renal cell carcinoma? A meta-analysis. World J Surg 2021; 45: 2191-2199
• 5 Sellner F, Tykalsky N, De Santis M. et al. Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: An indication for pancreatic surgery. Ann Surg Oncol 2006; 13: 75-85
• 6 Alt AL, Boorjian SA, Lohse CM. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117: 2873-2882
• 7 Ghavamian R, Klein KA, Stephens DH. et al. Renal cell carcinoma metastatic to the pancreas: Clinical and radiological features. Mayo Clin Proc 2000; 75: 581-585
• 8 Bassi C, Butturini G, Falconi M. et al. High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. Br J Surg 2003; 90: 555-559
• 9 Moussa A, Mitry E, Hammel P. et al. Pancreatic metastases: a multicentric study of 22 patients. Gastroentérologie Clin Biol 2004; 28: 872-876
• 10 Zerbi A, Ortolano E, Balzano G. et al. Pancreatic metastasis from renal cell carcinoma: Which patients benefit from surgical resection?. Ann Surg Oncol 2008; 15: 1161-1168
• 11 Moletta L, Milanetto AC, Vincenzi V. et al. Pancreatic secondary lesions from renal cell carcinoma. World J Surg 2014; 38: 3002-3006
• 12 Liaw C-C, Chuang C-K, Chang Y-H. The role of surgery in renal cell carcinoma with pancreatic metastasis. Biomed J 2015; 38: 173
• 13 Grassi P, Doucet L, Giglione P. et al. Clinical impact of pancreatic metastases from renal cell carcinoma: A multicenter retrospective analysis. PLOS ONE 2016; 11: e0151662
• 14 Jaen-Torrejimeno I, Rojas-Holguín A, López-Guerra D. et al. Pancreatic resection for metastatic renal cell carcinoma. A systematic review. HPB (Oxford) 2019; 22: 479-486
• 15 Blanco-Fernández G, Fondevila-Campo C, Sanjuanbenito A. et al. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID). Eur J Surg Oncol 2022; 48: 133-141
• 16 Barthet M, Giovannini M, Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019; 51: 836-842
• 17 Crinò SF, D’Onofrio M, Bernardoni L. et al. EUS-guided Radiofrequency ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: Feasibility, safety, and technical success. J Gastrointestin Liver Dis 2018; 27: 67-72
• 18 de Nucci G, Imperatore N, Mandelli ED. et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series. Endosc Int Open 2020; 08: E1754-E1758
• 19 Pai M. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015; 7: 52
• 20 Barthet M, Giovannini M, Gasmi M. et al. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021; 09: E1178-E1185
• 21 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
• 22 Chanez B, Caillol F, Ratone J-P. et al. Endoscopic ultrasound-guided radiofrequency ablation as an future alternative to pancreatectomy for pancreatic metastases from renal cell carcinoma: A prospective study. Cancers 2021; 13: 5267
• 23 Napoléon B, Lisotti A, Caillol F. et al. Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study). Gastrointest Endosc 2023; 98: 392-399
• 24 Kataoka K, Ishikawa T, Ohno E. et al. Differentiation between pancreatic metastases from renal cell carcinoma and pancreatic neuroendocrine neoplasm using endoscopic ultrasound. Pancreatology 2021; 21: 1364-1370
• 25 Bensalah K, Albiges L, Bernhard J-C. et al. Recommandations françaises du Comité de Cancérologie de l’AFU - Actualisation 2018–2020 : prise en charge du cancer du rein French ccAFU guidelines - Update 2018--2020: Management of kidney cancer. Progrès En Urol 2018; 28: R5-R33
• 26 Rini BI, Plimack ER, Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116-1127
• 27 Motzer RJ, Rini BI, McDermott DF. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20: 1370-1385
• 28 den Brok MHMGM, Sutmuller RPM, van der Voort R. et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64: 4024-4029
• 29 Wang X, Liu G, Chen S. et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia 2021; 38: 1519-1528
• 30 Wang K, Wang C, Jiang H. et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: Where we are and where to go. Front Immunol 2021; 12: 792781
• 31 Shi L, Chen L, Wu C. et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res 2016; 22: 1173-1184